Christie D Fowler1, Luis Tuesta, Paul J Kenny. 1. Laboratory of Behavioral and Molecular Neuroscience, Department of Molecular Therapeutics, The Scripps Research Institute-Florida, 130 Scripps Way, Jupiter, FL, 33458, USA.
Abstract
OBJECTIVE: Allelic variation in the α5 nicotinic acetylcholine receptor (nAChR) subunit gene, CHRNA5, increases vulnerability to tobacco addiction. Here, we investigated the role of α5* nAChRs in the effects of nicotine on brain reward systems. MATERIALS AND METHODS: Effects of acute (0.03125-0.5 mg/kg SC) or chronic (24 mg/kg per day; osmotic minipump) nicotine and mecamylamine-precipitated withdrawal on intracranial self-stimulation (ICSS) thresholds were assessed in wild-type and α5 nAChR subunit knockout mice. Noxious effects of nicotine were further investigated using a conditioned taste aversion procedure. RESULTS: Lower nicotine doses (0.03125-0.125 mg/kg) decreased ICSS thresholds in wild-type and α5 knockout mice. At higher doses (0.25-0.5 mg/kg), threshold-lowering effects of nicotine were diminished in wild-type mice, whereas nicotine lowered thresholds across all doses tested in α5 knockout mice. Nicotine (1.5 mg/kg) conditioned a taste aversion to saccharine equally in both genotypes. Mecamylamine (5 mg/kg) elevated ICSS thresholds by a similar magnitude in wild-type and α5 knockout mice prepared with minipumps delivering nicotine. Unexpectedly, mecamylamine also elevated thresholds in saline-treated α5 knockout mice. CONCLUSION: α5* nAChRs are not involved in reward-enhancing effects of lower nicotine doses, the reward-inhibiting effects of nicotine withdrawal, or the general noxious effects of higher nicotine doses. Instead, α5* nAChRs regulate the reward-inhibiting effects nicotine doses that oppose the reward-facilitating effects of the drug. These data suggest that disruption of α5* nAChR signaling greatly expands the range of nicotine doses that facilitate brain reward activity, which may help explain the increased tobacco addiction vulnerability associated with CHRNA5 risk alleles.
OBJECTIVE: Allelic variation in the α5 nicotinic acetylcholine receptor (nAChR) subunit gene, CHRNA5, increases vulnerability to tobacco addiction. Here, we investigated the role of α5* nAChRs in the effects of nicotine on brain reward systems. MATERIALS AND METHODS: Effects of acute (0.03125-0.5 mg/kg SC) or chronic (24 mg/kg per day; osmotic minipump) nicotine and mecamylamine-precipitated withdrawal on intracranial self-stimulation (ICSS) thresholds were assessed in wild-type and α5 nAChR subunit knockout mice. Noxious effects of nicotine were further investigated using a conditioned taste aversion procedure. RESULTS: Lower nicotine doses (0.03125-0.125 mg/kg) decreased ICSS thresholds in wild-type and α5 knockout mice. At higher doses (0.25-0.5 mg/kg), threshold-lowering effects of nicotine were diminished in wild-type mice, whereas nicotine lowered thresholds across all doses tested in α5 knockout mice. Nicotine (1.5 mg/kg) conditioned a taste aversion to saccharine equally in both genotypes. Mecamylamine (5 mg/kg) elevated ICSS thresholds by a similar magnitude in wild-type and α5 knockout mice prepared with minipumps delivering nicotine. Unexpectedly, mecamylamine also elevated thresholds in saline-treated α5 knockout mice. CONCLUSION: α5* nAChRs are not involved in reward-enhancing effects of lower nicotine doses, the reward-inhibiting effects of nicotine withdrawal, or the general noxious effects of higher nicotine doses. Instead, α5* nAChRs regulate the reward-inhibiting effects nicotine doses that oppose the reward-facilitating effects of the drug. These data suggest that disruption of α5* nAChR signaling greatly expands the range of nicotine doses that facilitate brain reward activity, which may help explain the increased tobacco addiction vulnerability associated with CHRNA5 risk alleles.
Authors: J E Henningfield; S R Goldberg; R I Herning; D R Jasinski; S E Lukas; K Miyasato; R Nemeth-Coslett; W B Pickworth; J E Rose; A Sampson Journal: NIDA Res Monogr Date: 1986
Authors: L M Marubio; M del Mar Arroyo-Jimenez; M Cordero-Erausquin; C Léna; N Le Novère; A de Kerchove d'Exaerde; M Huchet; M I Damaj; J P Changeux Journal: Nature Date: 1999-04-29 Impact factor: 49.962
Authors: Paul J Kenny; Elena Chartoff; Marisa Roberto; William A Carlezon; Athina Markou Journal: Neuropsychopharmacology Date: 2008-04-16 Impact factor: 7.853
Authors: Richard Sherva; Kirk Wilhelmsen; Cynthia S Pomerleau; Scott A Chasse; John P Rice; Sandy M Snedecor; Laura J Bierut; Rosalind J Neuman; Ovide F Pomerleau Journal: Addiction Date: 2008-09 Impact factor: 6.526
Authors: Deniz Bagdas; Clare M Diester; Jason Riley; Moriah Carper; Yasmin Alkhlaif; Dana AlOmari; Hala Alayoubi; Justin L Poklis; M Imad Damaj Journal: Neuropharmacology Date: 2019-06-18 Impact factor: 5.250
Authors: Taryn E Grieder; Morgane Besson; Geith Maal-Bared; Stéphanie Pons; Uwe Maskos; Derek van der Kooy Journal: Proc Natl Acad Sci U S A Date: 2019-11-27 Impact factor: 11.205
Authors: C Morel; L Fattore; S Pons; Y A Hay; F Marti; B Lambolez; M De Biasi; M Lathrop; W Fratta; U Maskos; P Faure Journal: Mol Psychiatry Date: 2013-12-03 Impact factor: 15.992